Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.77 - $21.47 $1.36 Million - $2.99 Million
139,400 New
139,400 $2.05 Million
Q3 2021

Nov 15, 2021

BUY
$19.74 - $28.7 $219,113 - $318,570
11,100 Added 32.84%
44,900 $940,000
Q2 2021

Aug 16, 2021

BUY
$20.49 - $35.63 $692,562 - $1.2 Million
33,800 New
33,800 $908,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.